Entasis Therapeutics Holdings
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Entasis Therapeutics Holdings generated cash of -$42,972,000, which is more than the previous year. Cash used in financing activities reached the amount of $22,102,000 last year. Net change in cash is therefore -$20,940,000.
Cash Flow
| 2016 | -15.95M | -140K | 42.19M |
|---|---|---|---|
| 2017 | -27.15M | -286K | 56.29M |
| 2018 | -35.81M | -36.09M | 66.16M |
| 2019 | -44.74M | 11.36M | 57K |
| 2020 | -45.42M | 24.98M | 57.65M |
| 2021 | -42.97M | -70K | 22.10M |
ETTX Cash Flow Statement (2016 – 2021)
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|
Cash at beginning of period | 53.24M | 16.03M | 49.36M | 55.10M | 26.25M | 157K |
Operating activities | ||||||
Net income | -47.14M | -50.49M | -43.85M | -32.95M | -29.92M | -19.09M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||
Depreciation and amortization | 104K | 141K | 142K | 164K | 194K | 177K |
Stock-based compensation expense | 4.02M | 2.95M | 2.42M | 1.20M | 420K | 570K |
| Deferred income tax benefit | 4.02M | 2.95M | 2.42M | 1.20M | 420K | 570K |
| Changes in operating assets and liabilities: | ||||||
Accounts receivable, net | 0 | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts payable | 513K | -644K | -30K | 133K | 447K | 641K |
Cash generated by operating activities | -42.97M | -45.42M | -44.74M | -35.81M | -27.15M | -15.95M |
Investing activities | ||||||
Purchases Of Investments | 0 | 0 | -44.95M | -35.72M | 0 | 0 |
Investments In Property Plant And Equipment | -70K | -18K | -105K | -370K | -286K | -140K |
Acquisitions Net | 0 | 0 | 0 | 0 | 0 | 0 |
Cash generated by investing activities | -70K | 24.98M | 11.36M | -36.09M | -286K | -140K |
Financing activities | ||||||
Common Stock Issued | 19.95M | 57.65M | 155K | 66.07M | 0 | 0 |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 0 | 0 | 0 | 0 | 0 | 0 |
Cash used in financing activities | 22.10M | 57.65M | 57K | 66.16M | 56.29M | 42.19M |
Net Change In Cash | -20.94M | 37.21M | -33.32M | -5.74M | 28.84M | 26.09M |
Cash at end of period | 32.30M | 53.24M | 16.03M | 49.36M | 55.10M | 26.25M |
| Data source | Data source | Data source | Data source |